HelioLiver™ 是一种用于早期发现肝癌的创新液体活检测试，现

StephenW

HelioLiver™ 是一种用于早期发现肝癌的创新液体活检测试，现已上市

发布时间：2021 年 12 月 6 日
2021 年 12 月 6 日 13:00 UTC

HelioLiver 可以通过简单的非侵入性抽血在最早阶段检测肝癌

HelioLiver 现在可通过提供者订单提供给患者

加利福尼亚州欧文市和坦普尔城--(美国商业资讯)-- Helio Health (“Helio”) 及其商业合作伙伴 Fulgent Genetics, Inc,（纳斯达克股票代码：FLGT）（“Fulgent”）今天宣布推出 HelioLiver ™，一种多分析物血液检测，结合无细胞 DNA (cfDNA) 甲基化模式和血清蛋白标记物，用于检测肝细胞癌 (HCC)——最常见的肝癌形式。 HelioLiver 可以在病变仍然很小的早期阶段检测到 HCC，而传统的标准护理成像工具往往无法做到这一点，并有可能启用更多已知的治愈性治疗方案，从而将五年存活率提高多达是癌症转移时的 13 倍。1,2

最近在 The Liver Meeting® 2021 上展示的数据概述了 HelioLiver 比目前可用的基于血液的测试具有更高的灵敏度。 HelioLiver 的特异性为 91%，在检测早期 HCC 方面的灵敏度为 76%，明显优于其他检测工具，如 AFP (57%)、GALAD (65%) 和超声 (47%)。3,4

Helio Health 美国首席执行官 Justin Chen Li 表示：“我们很高兴为肝癌高风险患者提供一种方便且灵敏的系列检测选择，以便在最重要的时候及早发现癌症。” “我们很自豪能与 Fulgent 合作推出这种创新、简单且可靠的测试，它有可能重新定义癌症测试的未来并促进更好的患者结果。”

HelioLiver 为可以在例行检查期间进行抽血的患者提供了一个简化的过程，为有患肝癌风险的人提供了一种快速、准确的方式来接受定期监测。虽然美国肝病研究协会 (AASLD) 指南建议对有风险的患者每六个月进行一次超声检查，但研究表明，由于通过以下方式进行检测不方便，只有 20% 的患者实际上接受了定期监测超声波。5 Helio 相信这个数字可以通过这种新的基于血液的测试显着增加。

Fulgent Genetics 首席商务官 Brandon Perthuis 表示：“通过与 Helio 的合作，我们的共同优先事项是以无缝方式将 HelioLiver 带给提供者和患者。 “利用我们广泛的商业基础设施，我们有能力为供应商提供轻松的订购体验，我们的代表随时准备在整个体验中提供一流的白手套服务。”

供应商可以在 HelioLiver.com/how-to-order 上在线下订单，通过电话 (+1 626-350-0537) 或发送电子邮件至 [email protected] 与代表取得联系。

有关 HelioLiver 及其临床性能的更多信息，请访问 www.HelioLiver.com。

StephenW

HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Cancer, is Now Commercially Available

Published: Dec 06, 2021
Dec. 6, 2021 13:00 UTC

HelioLiver can detect liver cancer in the earliest stages with a simple, non-invasive blood draw

HelioLiver is now available for patients through a provider order

IRVINE & TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Helio Health (“Helio”) and its commercial partner, Fulgent Genetics, Inc,  (NASDAQ: FLGT) (“Fulgent”), today announced the commercial launch of HelioLiver™, a multi-analyte blood test that incorporates cell free DNA (cfDNA) methylation patterns and serum protein markers for the detection of hepatocellular carcinoma (HCC) – the most common form of liver cancer. HelioLiver can detect HCC at its earliest stages when lesions are still very small, an area where traditional standard-of-care imaging tools often fall short, with the potential to enable more curative treatment options known to increase five-year survival rates by up to 13 times compared to when cancer has metastasized.1,2

Recent data presented at The Liver Meeting® 2021 outlined HelioLiver’s superior sensitivity over currently available blood-based tests. With a specificity of 91%, HelioLiver demonstrated 76% sensitivity in detecting early-stage HCC, significantly outperforming other detection tools such as AFP (57%), GALAD (65%), and ultrasound (47%).3,4

“We are excited to offer patients at high risk of developing liver cancer a convenient and sensitive serial testing option to catch cancer early when it counts the most,” said Justin Chen Li, U.S. Chief Executive Officer, Helio Health. “We are proud to partner with Fulgent to launch this innovative, simple, and reliable test that has the potential to redefine the future of cancer testing and foster better patient outcomes.”

HelioLiver offers a simplified process for patients with a blood draw that can be conducted during a routine check-up, providing a quick and accurate way to receive regular surveillance for people at risk of developing liver cancer. While the American Association for the Study of Liver Diseases (AASLD) guidelines recommend ultrasound screening every six months for patients who are at risk, studies have shown that as few as 20% of patients actually receive regular surveillance due to the inconvenience of accessing testing via ultrasound.5 Helio believes this number can dramatically increase with this new, blood-based test.

“Through our partnership with Helio, our joint priority is to bring HelioLiver to providers and patients in a seamless manner,” said Brandon Perthuis, Chief Commercial Officer, Fulgent Genetics. “Leveraging our extensive commercial infrastructure, we are well-positioned to deliver an easy ordering experience for providers with our representatives at the ready to provide the best-in-class white glove service throughout the entire experience.”

Providers can place orders online at HelioLiver.com/how-to-order, via phone (+1 626-350-0537) or email at [email protected] to get connected with a representative.

For more information about HelioLiver and its clinical performance, please visit www.HelioLiver.com.